TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06409130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499 placebo
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NNC0194-0499 placebo
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide placebo (Group A)
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo (Group A)
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide + semaglutide
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cagrilintide placebo
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide placebo (Group B)
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide placebo (Group B)
Description: Administered subcutaneously.
Study: NCT04857827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS-101
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate PF 0.5% ophthalmic solution
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Study: NCT05562739

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic
Description: multistrain postbiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in a form of a capsule for 6 weeks.
Study: NCT06617195

Intervention type: OTHER
Intervention: Exercise
Description: Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle

Intervention type: OTHER
Intervention: Exercise
Description: Young and older adults will perform a single bout of unaccustomed resistance exercise to evaluate molecular and cellular response in skeletal muscle
Study: NCT04898400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopy sleeve gastroplasty
Description: endoscopic procedure for weight loss
Study: NCT05039840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 IV
Description: Pharmaceutical form: solution Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344 SC
Description: Pharmaceutical form: solution Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Pharmaceutical form: solution Route of administration: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Pharmaceutical form: solution Route of administration: subcutaneous injection
Study: NCT06677203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT06675942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillation and Lung Expansion
Description: The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillation and Lung Expansion
Description: The OLE device (MetaNeb system) is a newer, noninvasive physiotherapy tool that combines mechanical and pharmacological interventions (aerosols) to help mobilize endobronchial secretions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation
Description: High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation
Description: High-frequency chest wall oscillation (HFCWO) is an airway clearance technique that uses external forces applied to the chest via an inflatable vest connected to a device that generates vibrations at varying frequencies and pressures.
Study: NCT06342921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg ADC189
Description: Use only once during the whole study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg ADC189
Description: Use only once during the whole study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use only once during the whole study.
Study: NCT04778839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
Study: NCT06613516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib is a selective inhibitor of the kinase activity of the serine/threonine Akt/PKB pathway that may potentially provide clinical benefit over a range of therapeutic indications. Capivasertib comes in capsule form in two forms; 160mg or 200mg
Study: NCT06619236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rina-S
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study: NCT06608212

Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY948862)
Description: Follow clinical practice/administration.

Intervention type: DRUG
Intervention: Others except finerenone
Description: Follow clinical practice/administration. The non-use finerenone treatment strategy will require individuals to be free of finerenone use.
Study: NCT06626022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Standard prostate mpMRI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExactVu
Description: microUltrasound
Study: NCT06615050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Description: Tablet or intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Description: Tablet or intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Description: Tablet or intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (Tac)
Description: Tablet or intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: Intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (Rux)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (Rux)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (Rux)
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Description: Tablet or intravenously (IV)
Study: NCT06683508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06684470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: mirtazapine will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be told to use 1 pill 1 hour before bedtime for the first week (7.5 mg po q.h.s.), 2 pills before bedtime during the second week of therapy (15 mg po q.h.s.), 3 pills (22.5 mg po q.h.s.) 1 hour before bedtime for the third week, and 4 pills (30 mg po q.h.s.) 1 hour prior to bedtime for the remainder of the study.
Study: NCT06684028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-JNU
Description: Patients will receive the novel tracer 68Ga-FAPI-JNU dose of approximately 2-5 mCi per person
Study: NCT06686927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids combined with immunoglobulin and romiplostim
Description: Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.~IVIG, 400mg/kg/d, intravenous administration, continuous administration for 3-5 days.~Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month.
Study: NCT06687772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa will be given intravenously twice daily on Days -5 and -4 over 120 minutes at a dose of 5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine will be given intravenously on Day -6 over 120 minutes at a dose of 400 mg/m\^2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Infusion of autologous peripheral blood stem cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anthracycline-based induction chemotherapy
Description: Standard of care, not dictated by protocol.
Study: NCT06685913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone supplement
Description: 100 mL flavoured drink containing 0.3 g/kg ketone monoester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate; ΔG®, University of Oxford; https://www.deltagketones.com) consumed 30 min prior to a mixed meal tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo with bitter agent to flavour match, consumed 30 min prior to a mixed meal tolerance test
Study: NCT06624072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 1
Description: Reference treatment (R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 1
Description: Reference treatment (R)
Study: NCT06382129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06624072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 1
Description: Reference treatment (R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 2
Description: when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 2
Description: when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerandomilast, Formulation 2
Description: when taken without food: Test Treatment 1 (T1) when taken with food: Test Treatment 2 (T2)
Study: NCT06681662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine Hydrochloride 30 mg/ml
Description: 0.15 mg/kg during induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: 1 ml during induction.
Study: NCT06624670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to spesolimab
Description: Placebo matching to spesolimab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone
Study: NCT06626061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress management in in person group Format
Description: The CBSM sessions will be delivered to participants in groups of ten, totaling eight sessions, each focused on a specific theme related to stress management. All participants will attend the complete sessions in person.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress management Hybrid Format
Description: The CBSM (hybrid) sessions will be offered to participants online, including a total of eight video modules, each dedicated to a specific theme related to stress management. Participants will also have access to three interactive virtual sessions, summary sheets in PDF format, and audio recordings for relaxation.
Study: NCT05625490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 Galmydar
Description: Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 Galmydar
Description: Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 Galmydar
Description: Intravenous injections of the PET radiotracer \[68Ga\]Galmydar.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13N-ammonia
Description: Two intravenous injections of PET radiotracer \[13N\]Ammonia.
Study: NCT06051617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar
Description: * Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or~* Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for up to 36 months.
Study: NCT06627517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Episodic overnight patch pump
Description: Subjects will wear the study device overnight for a period of 13 weeks in conjunction with use of Dexcom G6.
Study: NCT05369949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEX group
Description: Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.
Study: NCT04593953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLIP
Description: Injection of 40 ml of ropivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
Study: NCT05042752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CLINICAL ULTRASOUND
Description: The intervention group will receive the standard care of treatment in AHF and the performance of CU.
Study: NCT05305859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax combining chidamide and azacitidine (VCA)
Description: information already included in arm/group descriptions
Study: NCT05132660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Description: 25 mg carbidopa/100 mg levodopa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill of similar size/shape
Study: NCT05783947

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera
Description: Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.
Study: NCT05926843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation surgery (device) and motor rehabilitation
Description: The first part of the study will involve a preoperative evaluation. Participants' clinical history, neurological, neurophysiological and advanced brain/spine MRI examination will be assessed (Part 1). Subsequently, participants will undergo spinal cord stimulation surgery which involves the implantation of a medical device (Part 2). After the surgery, the research participants will be hospitalized at the Neurosurgery Unit (10 days) to monitor the incision site (Part 3). Thereafter, the patients will be moved (for at least 6 weeks) to the Rehabilitation Unit in order to identify appropriate stimulation parameters for inducing stepping and standing and for starting training. The combination of epidural stimulation with manual step/stand training will be thus evaluated (Part 4). Patients will be finally assessed by clinical evaluation, advanced MRI and neurophysiological examination to study the brain, spine and peripheral functions after six months (Part 5).
Study: NCT06317324

Intervention type: OTHER
Intervention: Different treatments
Description: NSCLC patients receive the treatment of SBRT
Study: NCT04958577

Intervention type: DEVICE
Intervention: Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)
Description: This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.

Intervention type: DEVICE
Intervention: Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)
Description: This device is a medical device but will be used only observationally--this device takes a patient's symptoms into account by asking questions and gives a ranked list of likely conditions that the patient might have based on the answers to these questions. The assessment report also includes urgency advice levels, that is, which care the patient should proceed to based on the condition suggestions. The WRA is used by the patient directly and the HDA is used by the doctor to ask the questions to the patient.
Study: NCT06778148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient AI for clinician documentation
Description: Ambient AI for clinician documentation
Study: NCT06777641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote supervision
Description: teacher use remote supervision to assist peer training
Study: NCT06092320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation on Pediatric Status Epilepticus
Description: The participants will complete a simulation session and debrief lead by a pediatric emergency medicine physician on status epilepticus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation on Pediatric Status Epilepticus
Description: The participants will complete a simulation session and debrief lead by a pediatric emergency medicine physician on status epilepticus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic Lecture on Pediatric Status Epilepticus
Description: The participants will complete a lecture on pediatric status epilepticus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic Lecture on Pediatric Status Epilepticus
Description: The participants will complete a lecture on pediatric status epilepticus
Study: NCT01845506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory monitor
Description: Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless pressure sensor
Description: Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.